Skip to content

Protagenic Therapeutics, Inc.new

PTIX

CIK 0001022899

← back to feed
Revenue (TTM)
$0
Q3 Mar 2026
Net Income (TTM)
−$5.16M
−10.5% YoY Q3 Mar 2026
EPS Diluted (TTM)
−$3.45
+1.7% YoY Q3 Mar 2026
Gross Margin
—
Q3 Mar 2026
Operating Margin
—
Q3 Mar 2026
Net Margin
—
Q3 Mar 2026
Free Cash Flow (TTM)
−$4.14M
Q3 Mar 2026
Cash
$191.67K
Q3 Mar 2026
Total Debt
—
Q3 Mar 2026
Shares Outstanding
1.81M sh
Q3 Mar 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings